Drugs / Hypidone
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03739632 | Nov 2018 → Dec 2019 | major depressive disorder | Zhejiang Huahai Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hypidone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03739632 ↗ |
| Route | Oral | “Hypidone Hydrochloride tablets will be given orally, twice daily, for 6 weeks” NCT03739632 ↗ |